User login
Key clinical point: Trifluridine/tipiracil plus bevacizumab (TT-B) appears to be a promising first-line therapeutic regimen for patients with unresectable metastatic colorectal cancer (mCRC) who are ineligible for intensive chemotherapy.
Major finding: The median overall survival (OS) with TT-B (22.3 months) vs capecitabine plus bevacizumab (C-B; 17.7 months) was longer by 4.6 months (adjusted hazard ratio 0.78; 95% CI 0.55-1.10). No new safety signals were observed.
Study details: The data are the final OS results of the phase 2 TASCO1 study that included 153 adult patients with unresectable mCRC who were randomly assigned to receive first-line TT-B (n = 77) or C-B (n = 76), with cycles repeated every 4 or 3 weeks, respectively.
Disclosures: The study was sponsored by Servier and Taiho. Some authors declared serving as advisory board members or meeting chairs of, or receiving research grants and travel and accommodation expenses from various organizations, including Servier and Taiho. The other authors are employees of Servier.
Source: Van Cutsem E et al. First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: Final survival analysis in the TASCO1 study. Br J Cancer. 2022;126:1548-1554 (Apr 19). Doi: 10.1038/s41416-022-01737-2
Key clinical point: Trifluridine/tipiracil plus bevacizumab (TT-B) appears to be a promising first-line therapeutic regimen for patients with unresectable metastatic colorectal cancer (mCRC) who are ineligible for intensive chemotherapy.
Major finding: The median overall survival (OS) with TT-B (22.3 months) vs capecitabine plus bevacizumab (C-B; 17.7 months) was longer by 4.6 months (adjusted hazard ratio 0.78; 95% CI 0.55-1.10). No new safety signals were observed.
Study details: The data are the final OS results of the phase 2 TASCO1 study that included 153 adult patients with unresectable mCRC who were randomly assigned to receive first-line TT-B (n = 77) or C-B (n = 76), with cycles repeated every 4 or 3 weeks, respectively.
Disclosures: The study was sponsored by Servier and Taiho. Some authors declared serving as advisory board members or meeting chairs of, or receiving research grants and travel and accommodation expenses from various organizations, including Servier and Taiho. The other authors are employees of Servier.
Source: Van Cutsem E et al. First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: Final survival analysis in the TASCO1 study. Br J Cancer. 2022;126:1548-1554 (Apr 19). Doi: 10.1038/s41416-022-01737-2
Key clinical point: Trifluridine/tipiracil plus bevacizumab (TT-B) appears to be a promising first-line therapeutic regimen for patients with unresectable metastatic colorectal cancer (mCRC) who are ineligible for intensive chemotherapy.
Major finding: The median overall survival (OS) with TT-B (22.3 months) vs capecitabine plus bevacizumab (C-B; 17.7 months) was longer by 4.6 months (adjusted hazard ratio 0.78; 95% CI 0.55-1.10). No new safety signals were observed.
Study details: The data are the final OS results of the phase 2 TASCO1 study that included 153 adult patients with unresectable mCRC who were randomly assigned to receive first-line TT-B (n = 77) or C-B (n = 76), with cycles repeated every 4 or 3 weeks, respectively.
Disclosures: The study was sponsored by Servier and Taiho. Some authors declared serving as advisory board members or meeting chairs of, or receiving research grants and travel and accommodation expenses from various organizations, including Servier and Taiho. The other authors are employees of Servier.
Source: Van Cutsem E et al. First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: Final survival analysis in the TASCO1 study. Br J Cancer. 2022;126:1548-1554 (Apr 19). Doi: 10.1038/s41416-022-01737-2